A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

NCT04700280 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated based on Sponsor decision

Conditions

Primary Sjögren Syndrome

Interventions

DRUG: GLPG3970
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV